<DOC>
	<DOCNO>NCT01493336</DOCNO>
	<brief_summary>This randomize , open-label , two-way crossover study evaluate relative bioavailabilty safety capecitabine rapid disintegrate tablet ( RDT ) versus commercial Xeloda tablet patient colorectal breast cancer . Patients randomized sequence single oral dos capecitabine RDT Xeloda Days 1 2 14-day treatment cycle Xeloda . Follow-up 30 day .</brief_summary>
	<brief_title>A Study Capecitabine Rapid Disintegrating Tablets ( RDT ) Versus Commercial Xeloda Patients With Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Histological/cytological confirmation colorectal breast cancer Patient ambulatory Karnofsky performance status &gt; 70 % Body surface area 1.5 2.0 m2 Either : Due receive Xeloda monotherapy combination therapy per treat physician 's treatment plan , Currently receive Xeloda monotherapy investigator 's opinion able tolerate study drug dose Day 1 Day 2 Any contraindication Xeloda Received Xeloda 6 day prior Day 1 Subjects organ allograft ( autologous bone marrow transplant high dose chemotherapy ) Renal impairment Pregnant lactating female Participation investigational drug study within 28 day prior screen Lack physical integrity upper gastrointestinal tract , clinically significant malabsorption syndrome Serious uncontrolled intercurrent infection History clinically significant coronary artery disease Concomitant treatment warfarin Known dihydropyrimidine dehydrogenase deficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>